Drug intelligence / Profile preview

Askprol-M

Development stage: Unknown
Lead developer: Citi Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Askprol-M** is an oral fixed-dose migraine analgesic product developed and manufactured by Citi Pharma. Each film-coated tablet contains paracetamol 250 mg, caffeine anhydrous 65 mg, and aspirin 250 mg. It is intended for symptomatic relief of migraine headache; paracetamol and aspirin provide analgesic activity, while caffeine is included as an analgesic adjuvant. ([citipharma.com.pk](https://www.citipharma.com.pk/formulations/))

Brand names: Askprol-M
Other names: aspirin + caffeine + paracetamol

Targets

CNR1 (Cannabinoid receptor 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Askprol-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Askprol-M.

Explore the full profile